A randomized, double-blind, placebo-controlled, multicenter, dose-range, proof-of-concept, 24-week treatment study of IVA337 in adult subjects with nonalcoholic steatohepatitis

  • Hodge, Alex, (Primary Chief Investigator (PCI))

Project: Research

AcronymNASH
StatusActive
Effective start/end date8/10/197/10/24

Keywords

  • clinical trial
  • treatment efficacy
  • steatohepatitis